PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.
You may also be interested in...
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.